Literature DB >> 10580192

An aerosol challenge mouse model for Moraxella catarrhalis.

W G Hu1, J Chen, F M Collins, X X Gu.   

Abstract

A simple, reproducible, and non-invasive mouse pulmonary clearance model for Moraxella catarrhalis via aerosol challenge was established. All of eight tested strains could be inoculated into mice at more than 10(5) colony-forming units (CFU)/lung with a challenge concentration of 1x10(9)-6x10(9) CFU/ml in a nebulizer. The number of bacteria retained at 6 h postchallenge was more than 10(4) CFU/lung while at 24 h postchallenge, approximate 10(3) CFU/ml or less remained in the lungs. A maximum of 100 mice could be challenged per aerosol exposure. The number of bacteria inoculated in the lungs could be adjusted by the bacterial challenge concentration, the exposure time, and the negative pressure. Lung tissue sections revealed that bacteria were evenly distributed in the lungs. Passive immunization significantly enhanced pulmonary clearance of the homologous strain in this model. These data indicate that this model will be useful for evaluating M. catarrhalis vaccine candidates and studying roles of immunity against M. catarrhalis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580192     DOI: 10.1016/s0264-410x(99)00335-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Role of the oligopeptide permease ABC Transporter of Moraxella catarrhalis in nutrient acquisition and persistence in the respiratory tract.

Authors:  Megan M Jones; Antoinette Johnson; Mary Koszelak-Rosenblum; Charmaine Kirkham; Aimee L Brauer; Michael G Malkowski; Timothy F Murphy
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

Review 2.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

3.  Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine.

Authors:  Xinan Jiao; Takashi Hirano; Yingchun Hou; Xin-Xing Gu
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

4.  Roles of 3-deoxy-D-manno-2-octulosonic acid transferase from Moraxella catarrhalis in lipooligosaccharide biosynthesis and virulence.

Authors:  Daxin Peng; Biswa P Choudhury; Ronald S Petralia; Russell W Carlson; Xin-Xing Gu
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

5.  Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins.

Authors:  W G Hu; J Chen; J F Battey; X X Gu
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

6.  Functional characteristics of a protective monoclonal antibody against serotype A and C lipooligosaccharides from Moraxella catarrhalis.

Authors:  W G Hu; J Chen; J C McMichael; X X Gu
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

7.  Moraxella catarrhalis bacterium without endotoxin, a potential vaccine candidate.

Authors:  Daxin Peng; Wenzhou Hong; Biswa P Choudhury; Russell W Carlson; Xin-Xing Gu
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

Review 8.  A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

9.  Characterization of proteins Msp22 and Msp75 as vaccine antigens of Moraxella catarrhalis.

Authors:  Elizabeth A Ruckdeschel; Aimee L Brauer; Antoinette Johnson; Timothy F Murphy
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

10.  Galactose residues on the lipooligosaccharide of Moraxella catarrhalis 26404 form the epitope recognized by the bactericidal antiserum from conjugate vaccination.

Authors:  Shengqing Yu; Hang Xie; Anup Datta; Natasha Naidu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2008-06-16       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.